Compare Gilead Sciences, Inc. (GILD) vs Levi Strauss & Co. (LEVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Levi Strauss & Co. — how do they compare? Gilead Sciences, Inc. trades at $133.4 (market cap $163.51B), while Levi Strauss & Co. trades at $24.8 (market cap $9.19B). The key difference: Gilead Sciences, Inc. is far larger — about 17.8× Levi Strauss & Co.'s market cap, and Levi Strauss & Co. pays the higher dividend (2.68%). Which is the better fit depends on your goals.
| GILD | LEVI | |
|---|---|---|
Market Cap | $163.51B | $9.19B |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $24.83 |
52-Week Low | $108.22 | $17.92 |
Enterprise Value | $178.05B | $10.51B |
Dividend Yield | 2.49% | 2.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Levi Strauss & Co. (LEVI) trades at $23.79, down 1.65% on the day, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.28, beating expectations of $0.24, and raised its full-year outlook. Analyst consensus is strongly bullish with 15 buy ratings and a $28.00 price target. Recent dividend increases and robust digital strategy execution highlight operational strength, though stock performance faces near-term pressure from tariff and forex concerns.
Outlook remains positive with earnings momentum and strategic initiatives driving growth, but investors face risks from macroeconomic volatility and competitive pressures. The stock offers potential upside to consensus targets if execution continues, though technical weakness suggests cautious entry timing. Balanced risk-reward with fundamental support outweighing short-term sentiment headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Levi Strauss & Co.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →
